CASE HISTORY: A 14-year-old neutered male Sealyham terrier was referred for assessment of a persistent pyoderma. It had experienced numerous episodes of dermatitis involving pododermatitis, pyoderma and otitis over the previous 6 years.
Introduction
Approximately 50% of healthy dogs are colonised by Staphlococcus pseudintermedius (SaijonmaaKoulumies and Lloyd 1995; Harvey and Noble 1998) . Although primarily isolated from the oral, nasal and peri-anal regions, transient colonisation of other sites may occur. S. pseudintermedius is an opportunistic pathogen and may cause canine skin and ear infections. The S. pseudintermedius strain causing an infection is usually the same as the colonising strain (Pinchbeck et al. 2006) . Antimicrobial treatment may include the use of oral and topical antimicrobials, and biocides. In New Zealand β-lactam antimicrobials such as amoxicillin-clavulanic acid and cephalosporins are empirically used.
Microbiological culture is reported to not be routinely performed for suspected canine pyoderma and is reserved for cases that respond poorly to antimicrobials or relapse frequently (Pleydell et al. 2012) .
Isolates of S. pseudintermedius resistant to methicillin were initially reported in the early to mid 2000s in the United States of America, Europe and Asia, and have subsequently become a significant problem in veterinary medicine (Frank and Loefffler 2012) . Similar to methicillin resistance in Staphylococcus aureus, resistance in S. pseudintermedius is mediated by the production of a modified penicillin binding protein (PBP2a) which is produced by the mecA gene. MecA is located on a chromosomal mobile element called the staphylococcal chromosomal cassette which can be transferred between staphylococci (Harrison et al. 2014) . Regional clonal spread of methicillinresistant S. pseudintermedius (MRSP) has been reported in several countries including Australia (Perreten et al. 2010; Siak et al. 2014) . Globally, MRSP are usually resistant to multiple classes of antimicrobials and can be resistant to all veterinary-licensed antimicrobials (van Duijkeren et al. 2011) . There is no evidence that MRSP are more virulent than methicillin-susceptible S.
pseudintermedius, but successful antimicrobial treatment of canine pyoderma associated with MRSP can be difficult.
Here we report the first isolation of mecA-positive multidrug-resistant S. pseudintermedius in New Zealand. 
Case History

Clinical findings
The dog appeared well on presentation at the Allergy and Dermatology Clinic on the 2 May 2014.
The owner reported good exercise tolerance, normal appetence, consistent weight and unchanged water intake.
On examination, a yellow mucoid exudate was present about both nares which were crusted dorsally.
The lower lips were crusted with haemopurulent exudate. Epidermal collarettes were present on the trunk with more lesions dorsally and laterally than ventrally. There were peri-anal crusts. Mild erythema was present on the concave aspect of both pinnae. The feet were normal. Peripheral lymph nodes were normal size.
Cytology, performed on the nasal exudate and skin lesions, revealed neutrophils and numerous cocci.
Red blood cells were also present in exudate from the lower lip lesions. Trichograms involving approximately 200 hair shafts were negative for Demodex mites.
A diagnosis of mucocutaneous pyoderma, superficial spreading pyoderma and focal deep pyoderma was made. Interim treatment was 100 mg cefpodoxime (Simplicef, Zoetis, Auckland, NZ) given orally once per day.
Microbiological findings
Staphylococcus pseudintermedius was isolated from the nasal exudate. Colony morphology, when cultured aerobically on blood agar was typical for staphylococci. The colonies were catalase-positive, DNase-positive, hyaluronidase-negative and polymyxin B-sensitive, indicating a Staphylococcus species from the intermedius group. Identification as S. pseudintermedius was performed using matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF-MS) (Decristophoris et al. 2011) , using a Bruker Daltonik GmbH microflex, version 1.3 (Bruker Daltonik GmbH, Bremen, Germany) with the dervied spectra compared to a validated reference database (Maldi biotyper version 3.1; Bruker Daltonik GmbH).
Antimicrobial susceptibility testing was performed using Kirby-Bauer disc diffusion. Zone diameters were interpreted according to the Clinical Laboratory Standards Institute (Anonymous 2008 (Anonymous , 2010 .
The isolate was resistant to numerous antimicrobials including oxacillin (Table 1) . Resistance to oxacillin (a surrogate for methicillin) can sometimes occur in isolates without the mecA gene (Frank and Loeffler 2012) , so the isolate was referred to the Institute of Environmental Science and Research (Porirua, NZ). The presence of the mecA gene was confirmed by PCR according to the method of Maes et al. (2002) .
Swabs of the owner's nose were collected by their medical practitioner and were negative for S.
pseudintermedius when tested in a medical laboratory. Swabs of the nose, lips and anus of the other dog in the household were similarly negative when tested by Gribbles Veterinary Pathology (Hamilton, NZ).
Genetic relatedness of the isolate to MRSP isolated in Western Australia (Siak et al. 2014 ) was determined using pulsed field gel electrophoresis (PFGE). The PFGE was carried out in the same laboratory and under the same conditions as described by Siak et al. (2014) , and used SmaI (Roche Diagnostics, Auckland, NZ) and cfr91 (ThermoFisher Scientific, Scoresby, Victoria, Australia) restriction enzymes as described by Perreten et al. (2013) . The pulse times were 5-40 seconds over 18 hours and 20-25 seconds over 5 hours. Chromosomal patterns were examined visually and scanned with a Quality One device (Bio-Rad Laboratories Pty Ltd, Auckland, NZ). The unweighted pair group method with arithmetic mean was used to assess relatedness, with settings for tolerance and optimisation of 1.25% and 0.5%, respectively. Isolates with ≥80% similarity were considered the same pulsotype. The PFGE pulsotype of the isolate from the case described here was found not to be related to the Western Australian isolates, on the basis of <80% similarity. The latter strain was related to the internationally known sequence type (ST)68 (Siak et al.2014 ).
Treatment
Oral antimicrobial treatment was changed on the 10 May 2015 to 100 mg per day rifampicin (Rifadin, Aventis, Auckland, NZ) given orally for 2 weeks. The choice of rifampicin was based on the results of Kirby-Bauer sensitivity tests, the first author's 20-year experience of its use in deep pyoderma, its ability to achieve effective concentrations in neutrophils (Nielson and Black 1999) and evidence that it has the potential to kill staphylococci in carriage sites (Mollema et al. 2010) . It was planed to be used in 2-week-course separated by a 2-week interval to minimise the risk of hepatoxicity. A topical cream containing mupirocin (Bactroban Cream, GlaxoSmithKline Ltd, Auckland, NZ) was applied to the nose, lips and anus 2-3 times daily. Weekly washing with a chlorhexadine shampoo (Pyohex, Zoetis) was also carried out.
After the 2-week course of rifampicin, treatment with 100 mg per day cefpodoxime was initiated. A clinical response to the first 2 weeks of rifampicin treatment was observed, but the change to cefpodoxime resulted in exacerbation of the lesions after 1 week. The choice of cefpodixime was based on the intermediate Kirby-Bauer sensitivity to cefitoxin and was made before the PCR result was available. It was substituted on 13 June 2014 with approximately 13 mg/kg enrofloxacin (Baytril, Bayer NZ Ltd) given once daily. Toward the end of this phase of treatment, the nasal, skin and anal lesions had resolved although some crusting remained on the lower lips.
Inappetance and lethargy were observed at this time and blood and urine tests were performed. The urine specific gravity was 1.047, with high protein concentrations and moderate blood present. A complete blood count showed a moderate anaemia that was strongly regenerative. Further urine testing showed a urine protein:creatinine ratio of 1.0 (>0.5 is considered consistent with renal disease). The dog collapsed the next day with a temperature of 41°C. Ultrasonographic examination detected an abnormality of one kidney. The owner declined further testing and requested euthanasia on 24 June 2014. Post-mortem examination was not permitted.
Discussion
Globally, infection with MRSP is a major clinical problem for dogs, owners and veterinarians. Clonal spread has been a feature in many regions with ST71 the most frequently identified clone in Europe and ST68 in North America (Perreten et al. 2010) . In addition to mecA, most MRSP strains carry resistance genes to several different classes of antimicrobials (Perreten et al. 2010) .
While nosocomial infections do occur, transmission is primarily from asymptomatic carriers to infection-vulnerable dogs (Pinchbeck et al) . Dogs may be colonised by MRSP for >12 months after infection (Windahl et al. 2012 ). MRSP does not appear to be more virulent than methicillinsusceptible S. pseudintermedius. Treatment of MRSP carriers is not recommended in countries where MRSP has become established. (Frank and Loeffler 2012) . However in countries with low MRSP prevalence, decolonisation treatment may be a reasonable strategy to limit its transmission.
Strategies need to be adapted to particular environments to prevent the transmission of MRSP in low prevalence countries. In New Zealand there are many opportunities for dogs to interact freely; dog competitions, day-care facilities and boarding kennels all present particular risks for exchange of S.
pseudintermedius. Veterinary clinics are a risk because they will have more infection-vulnerable dogs than in the wider environment. Preventive measures may include scheduling appointments at veterinary clinics for pyoderma-affected dogs distant from debilitated or pyoderma-prone dogs, in addition to hygiene measures within the facility.
Because MRSP is frequently multidrug resistant, treatment of MRSP-associated pyoderma can be difficult. For this reason it would seem reasonable for an island nation to create barriers to the importation of overseas clones that have spread epidemically. In the case described here the organism was not detected in the carriage sites of the owner or companion dog, and no further MRSP were isolated in the following 15 months (C. Douglass, unpublished data), suggesting that this isolate was unlikely to be a successful clone. One major veterinary pathology laboratory in New Zealand has been using oxacillin Kirby-Bauer discs routinely for >2 years (C. Douglass, unpublished data) and the other The history of New Zealand having predominantly international strains of MRSA (Heffernan and Bakker 2011), rather than local strains, and the finding that international travel plays a significant role in transmission of MRSA with carrier or infected humans (Zhou et al. 2014) would support the use of border controls to detect dogs carrying MRSP.
The unavailability of oral chloramphenicol in New Zealand limits the choice of antimicrobials for treating MRSP infections. Although rifampicin and enrofloxacin were effective in this dog, rifampicin is difficult to use because of potential hepatotoxicity and both rifampicin and fluoroquinalones have been associated with the emergence of antimicrobial resistance. Topical antimicrobials used with shampoos have also been shown to be useful but resistance to some topical antimicrobials has been reported, and topical treatment of deep pyoderma is considered adjunctive rather than primary (Miller et al. 2013) .
The detection of MRSP in New Zealand is a public health concern, and should prompt increased vigilance in assessing response to antimicrobial treatment of canine pyoderma and the use of microbiological investigation, including susceptibility testing to oxacillin when response is doubtful. 
